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Abstract: Condyloma acuminata is an infectious disease caused by the human papilloma virus (HPV)
and one of the most common sexually transmitted infections. It is manifested as warts that frequently
cause pain, pruritus, burning, and occasional bleeding. Treatment (physical, chemical, or surgical)
can result in erosion, scars, or ulcers, implying inflammatory processes causing pain. In this work,
a biocompatible topical hydrogel containing 2% ketorolac tromethamine was developed to manage
the painful inflammatory processes occurring upon the removal of anogenital condylomas. The
hydrogel was physically, mechanically, and morphologically characterized: it showed adequate
characteristics for a topical formulation. Up to 73% of ketorolac in the gel can be released following a
one-phase exponential model. Upon application on human skin and vaginal mucosa, ketorolac can
permeate through both of these and it can be retained within both tissues, particularly on vaginal
mucosa. Another advantage is that no systemic side effects should be expected after application of
the gel. The hydrogel showed itself to be well tolerated in vivo when applied on humans, and it did
not cause any visible irritation. Finally, ketorolac hydrogel showed 53% anti-inflammatory activity,
suggesting that it is a stable and suitable formulation for the treatment of inflammatory processes,
such as those occurring upon chemical or surgical removal of anogenital warts.
Keywords: Condyloma acuminata; ketorolac; pain management; alginate hydrogel; topical delivery;
transdermal; mucosal delivery; mucoadhesive; anti-inflammatory
1. Introduction
Condyloma acuminata (CA) is one of the most common sexually transmitted infec-
tions [1] caused by various genotypes of Human Papilloma Virus (HPV) [2]. There are
more than 180 genotypes described, around 40 of which have been related to anogenital
warts, most particularly genotypes 6 and 11 [3]. Genotypes 16 and 18 attracted attention
because of their oncogenic nature and they have been associated to vaginal cervix cancer
and anus cancer [4].
Although the introduction of the tetravalent vaccine against HPV caused a significant
reduction in its incidence [5], the disease incidence is still high, especially in certain
countries with socio-economic issues [5]. CA can affect both sexes at any age, being the
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maximum incidence is between 20- and 24-year-old women and between 25- and 29-year-
old men [6]. Symptoms associated to CA depend on anatomical location, number, and size
of the lesions [3], being pruritus the most frequent, followed by leukorrhea, discomfort,
bleeding and pain. In addition, CA usually involves psychological aspects such as concern,
shame, and lack of self-esteem in the sexual sphere [1].
On some occasions CA can be resolved spontaneously or will remain with no change,
but in other cases lesions need to be treated, specially to prevent future outcomes such
as cancer. In these cases, a therapeutic intervention should be carried out, considering
location of the disease, number of warts, and patient related aspects such as life-style, and
economic considerations, among others [6]. Several theories are described in the literature
but there is not enough scientifical evidence demonstrating one treatment to be superior
over others [7]. Pharmacological treatment involves an immunomodulatory approach
(topical imiquimod, podophyllotoxin, and sinecatechins of tea extract), physical agents
(cryotherapy, trichloroacetic acid, electrocoagulation, and CO2 laser), and/or surgery.
Other treatments backed up less scientific evidence due to the few clinical trials, involve
intralesional interferon, photodynamic therapy, and topical cidofovir [8]. Unfortunately,
when there is intravaginal or intra-anal CA, the treatment alternatives are reduced, and on
some occasions, surgery is the only option.
Pain management is under extensive study so that it may improve patient quality
of life and reduce the post-surgery discomfort. Ambulatory and minor surgeries usually
combine anesthetics, analgesics, and anti-inflammatory drugs in different pre, intra, or
post-operative regimes. Ketorolac is a non-steroidal anti-inflammatory drug with potent
analgesic properties close to those of opioids, with no addictiveness potential and no
sedative properties [9]. Several authors injected surgery ketorolac at the anatomical site
(colon or vaginal), with local effect, in haemorrhoidectomy [10] and other colon and vaginal
surgical procedures [11]. It resulted in successful pain management and improvement
in the patient’s recovery. Ketorolac demonstrated to be effective in the management of
postoperative pain when administrated in a single dose [12]. It is also administrated
topically as preoperative medication in eye laser keratectomy and cataracts [13–15]. In fact,
one of the most common applications of topical ketorolac has been in ophthalmology, with
very low topical administration in skin and mucosa. Considering the successful results
in pain management after local injection in colon and vaginal surgeries, as previously
described, topical ketorolac is proposed is proposed for intravaginal application, pre-
vaginal applications and/or anal application in CA removal.
Two main events modulate the successful topical delivery: diffusion through the
vehicle towards the surface of the tissue (in this case, skin or vaginal mucosa) and the
partitioning between the vehicle and the tissue. For this reason, several aspects should be
considered during the development. On one hand, the physicochemical properties of the
drug modulate its intrinsic permeability, being the molecular weight and the log P (octanol–
water partitioning) the main parameters used to predict successful permeation. On the other
hand, characteristics of the formulation also modulate the permeation, such as the complete
solution of the drug in the vehicle, the particle size (in suspensions), pH, relative polarity
between formulation-drug-body surface, and the presence of permeation enhancers.
As well, the biocompatibility of the formulation is essential for treatment tolerance and
patient compliance. Hydrogels are traditional formulations composed of different polymers
types, natural ones (different cellulose grades and other polysaccharides) or synthetic ones
(polyacrylates, polyvinyl pyrrolidone, etc.) All these polymers are able to retain water
in their 3D network by creating hydrogen bonds between water molecules and polymer
molecules. Alginate is a natural linear copolymer formed by (1,4)-β-D-mannuronic acid and
α-L-guluronic acid residues, which can be arranged as homopolymeric sequences of each
residue, or with alternating residues. Alginate-based gels show interesting mucoadhesive
properties and a very good compatibility profile [16], having been extensively used in
topical drug delivery systems with successful results.
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In this work, we designed and developed a hydrogel using sodium alginate as the
gelator polymer and ketorolac tromethamine (Figure 1) as a potent non-steroidal anti-
inflammatory drug, as a candidate for the local pre- or post-treatment of inflammatory
processes derived from CA surgical removal. The hydrogel has been extensively character-
ized in terms of appearance, microscopic morphology, and mechanical properties, among
others. As well as this, its biopharmaceutical properties have also been investigated in
terms of drug release, drug permeation across the skin and vaginal mucosa, and the amount
of drug retained within the tissue after application for performing a local therapeutical
activity. Moreover, the biocompatibility of the formulation has been tested by measuring
the trans-epidermal water loss (TEWL) in humans, and the anti-inflammatory efficacy of
the ketorolac hydrogel (KT hydrogel) has been evaluated in mice. Results from this work
show that this hydrogel is a promising candidate for the described indication.
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Figure 1. Chemical structures of sodium alginate polymer and ketorolac tromethamine.
2. Results and Discussion
2.1. Physical Characterization of KT Hydrogel
2.1.1. Appearance and pH Evaluation
KT hydrogel when freshly prepared showed a yellowish-translucent color, stickiness
and limited fl wability. Th gel showed a neutral pH of 7.3. None of these aspects chang d
fter two month-storage at room temper ture.
2.1.2. Optical Stability
The stability of the hydrogel was studied by observing if any change occurred in
the backscattered light from the hydrogel using TurbiScanLab® equipment. The analysis
of changes in backscattered light, from the bottom to the top of the sample permits the
detecting of sedimentation/creaming processes of colloidal dispersions, as well as coales-
cence/flocculation processes, with a much higher sensitivity as compared to the naked
eye [17,18].
The hydrogels (with ketorolac tromethamine and without the drug) freshly prepared
were examined every hour for 24 h to observe potential changes in the short term. After
two-months of storage at room temperature (23 ± 2 ◦C), the analysis was repeated to
assess the stability in the long term. Figure 2 shows the backscattered light from a hydrogel
without drug (A–B) and with ketorolac tromethamine (C–D), both at day 1 (A,C) and at
day 60 (B, D), where the color of the lines shows the hourly evolution within the day of
analysis, being magenta the first and red the last analysis after the 24-h study.
As it can be observed in the figure, both the hydrogel alone and with ketorolac
tromethamine are mainly translucent, as the mean backscattered light is only around 6%
in all cases, indicating that the inclusion of ketorolac tromethamine in the formulation
does not affect the structure of the hydrogel and the drug remains in perfect solution.
Moreover, neither the hydrogel alone nor the hydrogel with ketorolac tromethamine
undergo sedimentation or creaming processes, as no significant increase/decrease in the
backscattered light in the bottom/top of the sample is observed. For colloidal samples
having a particle size bigger than 0.6 µm in diameter, flocculation is detected by the
decrease of the mean backscattering values throughout the sample [17]. In this case, the
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24-h evolution shows very little change (<1%) in the mean backscattered light of the freshly
prepared KT hydrogel (day 1), suggesting a reversible restructuration of the gel fibers
during the first 24 h, but with no evident flocculation process occurring, as the mean
backscattered light on day 60 remained stable. These results therefore show that the KT
hydrogel can be considered stable.
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2.1.3. Morphological Studies
Scanning Electron Microscopy (SEM) was used to evaluate the morphology of the KT
hydrogel. Figure 3 shows that the gel is composed of sodium alginate polymer that self-
assembles in the presence of water forming fibers that can be as thin as 80 nm in diameter.
The sodium alginate-fibers can grow resulting in two different arrangements and therefore
morphologies (Figure 3A,B). Fibers can grow longitudinally to several micrometers in
length and can gradually attach to each other to form thicker fibers. Fibers of different
thicknesses are intertwined and create pores with diameters ranging between 400 nm and
up to one micrometer.
The high porosity as well as the hydrophilic behavior of the fibers is ideal from a drug
delivery point of view, as it could permit the incorporation of solvent, and explains the
high and fast swelling observed. In addition, it could predict a fast diffusion of the drug
during drug release experiments (see below).
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association) model (D) Degradation of KT hydrogels in PBS. Inset shows a 7% weight increase during the first hour, in 
accordance to swelling results. After one hour, degradation follows a one-phase exponential decay kinetics. Values repre-
sent Means ± SD (n = 3). (E) Rheogram of KT hydrogel at 32 °C. The flow curve represents shear stress (τ in Pa) (left axis) 
or viscosity (η in Pa·s) (right axis) as a function of the shear rate (γ in s−1). 
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were immersed in PBS, and their weight was recorded at certain intervals. Figure 3C 
shows that previously dehydrated gels are highly hygroscopic, as they can incorporate up 
to 20 times their weight in water in less than 5 min. The weight increase followed a first 
order kinetics (one-phase exponential association), with a constant value k = 0.68 min−1. 
Moreover, degradation experiments were performed by immersing the KT hydrogels 
in PBS and recording their weight at certain intervals. Figure 3D shows an initial 7% 
weight increase during the first hour upon immersion, corresponding to the incorporation 
of PBS into the matrix, and which is in accordance with swelling experiments. After the 
first hour, the gel weight decreased following a first-order kinetics (one-phase exponential 
decay), with a degradation constant value of 0.21 h–1, therefore achieving 10% of the orig-
inal weight after 21 h. This weight loss corresponds to the gradual diffusion of the com-
ponents of the hydrogel into the medium, indicating that the formulation could be suc-
cessfully degraded when immersed in the biological medium. 
Figure 3. Characterization of KT hydrogel. (A,B) SEM images of KT hydrogel at different magnifications. The gel is formed
by sodium alginate polymers that self-assemble to form fibers with diameters of around 100 nm. Scalebar represents 5 µm.
(C) Swelling ratio of KT hydrogels upon immersion in PBS. The kinetics followed a first-order (one-phase exponential
association) model (D) Degradation of KT hydrogels in PBS. Inset shows a 7% weight increase during the first hour, in
accordance to swelli g results. After one hour, deg adation follows a one-phas ex on ial decay kinetics. V lues represent
Means ± SD (n = 3). (E) Rheogram of KT hydrogel at 32 ◦C. The flow curve represents shear stress (τ in Pa) (left axis) or
viscosity (η in Pa·s) (right axis) as a function of the shear rate (γ in s−1).
2.1.4. Swelling and Degradation Tests
Swelling experiments were performed in KT hydrogels to evaluate their ability to
incorporate solvent beneath the matrix. Briefly, previously dehydrated KT hydrogels were
immersed in PBS, and their weight was recorded at certain intervals. Figure 3C shows that
previously dehydrated gels are highly hygroscopic, as they can incorporate up to 20 times
their weight in water in less than 5 min. The weight increase followed a first order kinetics
(one-phase exponential association), with a constant value k = 0.68 min−1.
Moreover, degradation experiments were performed by immersing the KT hydrogels
in PBS and recording their weight at certain intervals. Figure 3D shows an initial 7% weight
increase during the first hour upon immersion, corresponding to the incorporation of PBS
into the matrix, and which is in accordance with swelling experiments. After the first hour,
the gel weight decreased following a first-order kinetics (one-phase exponential decay),
with a degradation constant value of 0.21 h–1, therefore achieving 10% of the original
weight after 21 h. This weight loss corresponds to the gradual diffusion of the components
of the hydrogel into the medium, indicating that the formulation could be successfully
degraded when immersed in the biological medium.
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2.1.5. Rheological Behavior
The mechanical properties of the KT hydrogel were studied by performing rheology
studies, where the shear rate was first increased and subsequently decreased, while shear
stress (τ) and the viscosity (η) were measured. The flow curve of KT hydrogels (Figure 3E)
(n = 2) indicated no thixotropic behavior in the system as the rheogram did not display
any hysteresis loop. The mathematical model that provided the best overall match of the
experimental data according to the highest correlation coefficient of regression (r) was
Cross, which indicates a shear thinning (pseudoplastic) behavior. Additionally, the results
indicated that the viscosity of the different samples at 100 s–1 was 2555.5 ± 28.5 mPa·s,
showing good repeatability of the rheological results between samples and indicating an
adequate formulation protocol.
2.2. In Vitro Release of Ketorolac from the Hydrogel
In vitro drug release experiments were performed using Franz-type cells to evaluate
the ability of the hydrogel to release the drug according to previously reported method-
ologies [19]. Figure 4 shows the cumulative amount of ketorolac released from the hydro-
gel. Different models were fitted (Zero-order, first-order and Higuchi) (see Appendix A,
Tables A1 and A2), and the best-fitting model was chosen according to the determination
coefficient (r2). Ketorolac released from the hydrogel followed a first order (one-phase
exponential association) kinetics, and the release parameters can be seen in Table 1.
Gels 2021, 7, x FOR PEER REVIEW 7 of 22 
 
 
2.1.5. Rheological Behavior 
The mechanical properties of the KT hydrogel were studied by performing rheology 
studies, where the shear rate was first increased and subsequently decreased, while shear 
stress (τ) and the viscosity (η) were measured. The flow curve of KT hydrogels (Figure 3E) 
(n = 2) indicated no thixotropic behavior in the system as the rheogram did not display 
any hysteresis loop. The mathematical model that provided the best overall match of the 
experimental data according to the highest correlation coefficient of regression (r) was 
Cross, which indicates a shear thinning (pseudoplastic) behavior. Additionally, the results 
indicated that the viscosity of the different samples at 100 s–1 was 2555.5 ± 28.5 mPa·s, 
showing good repeatability of the rheological results between samples and indicating an 
adequate formulation protocol. 
2.2. In Vitro Release of Ketorolac from the Hydrogel 
In vitro drug release experiments were performed using Franz-type cells to evaluate 
the ability of the hydrogel to release the drug according to previously reported method-
ologies[19]. Figure 4 shows the cumulative amount of ketorolac released from the hydro-
gel. Different models were fitted (Zero-order, first-order and Higuchi) (see Appendix A, 
Table A1 and Table A2), and the best-fitting model was chosen according to the determi-
nation coefficient (r2). Ketorolac released from the hydrogel followed a first order (one-
phase exponential association) kinetics, and the release parameters can be seen in Table 1. 
 









































































Figure 4. Cumulative amount of ketorolac released. Data followed a first-order (One-phase exponen-
tial association) kinetics. Values represent Means ± SD (n = 6).
Table 1. Drug release parameters from KT hydrogel according to a first order kinetics. Ymax =
total amount of drug released; K = release rate constant. Values represent Means ± 95% confidence
interval (n = 6).
Best-Fit Values
Ymax (µg/cm2) 2568 ± 14
K (h–1) 0.64 ± 0.12
Half-time (h) 1.08
R2 0.9908
Results show that the hydrogel can release up to 2568 µg/cm2 of ketorolac, corre-
sponding to 73% of the total dose seeded, and this maximum amount is already achieved
within 4 h, showing a release rate of 0.64 h–1. This fast drug release is in accordance with
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the wide and numerous pores created by the fibers arrangement, as observed in the SEM
images (Figure 3A,B), which allow the easy diffusion of the drug.
2.3. Ex Vivo Permeation of Ketorolac through Human Skin and Vaginal Mucosa
Permeation experiments were performed ex vivo to assess the permeation of ketorolac
across human skin as well as across vaginal mucosa according to previously reported
methodologies [9,20,21], in both cases under an infinite-dose regimen [22]. The cumulative
amount of ketorolac permeated through each tissue along time is shown in Figure 5A, and
the permeation parameters calculated can be seen in Table 2.
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an infinite dose regimen. (C) Biodistribution of ketorolac 24 h after application of KT hydrogel 
using a finite dose regimen. Around 95% ketorolac remains outside the skin while the successfully 
penetrated ketorolac is retained within the stratum corneum and epidermis layers. All values rep-
resent Means ± SD (n = 6). Different Greek letters represent significant differences (p < 0.001). 
Permeation of ketorolac across different tissues (skin or vaginal mucosa) upon appli-
cation of KT hydrogel showed significant differences. In case of permeation across skin 
tissue, the permeation parameters indicate that ketorolac permeation reached the steady 
state from the very beginning, with an estimated Tlag of 0.67 h, and showing a transdermal 
flux of 50.92 μg/h·cm2, leading to a total amount of ketorolac permeated of 1202.46 μg/cm2 
after 24 h. In contrast, permeation through vaginal mucosa indicated a slightly longer Tlag 
(2.04 h) while a significantly higher flux (306.00 μg/h·cm2) led to a similar amount of ke-
torolac permeated (1102.20 μg/cm2) in only 6 h. 
Table 2. Transdermal/transmucosal permeation parameters of ketorolac 24 h/6 h after application 
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Figure 5. (A) Cumulative amount of ketor lac permeat d (µg/cm2) through human skin a d through
vaginal mucosa upon application of KT hydrogel. (B) Total amount of ketorolac retained within the
tissue (µg/g cm2) (skin or vaginal mucosa) 24-h after application of KT hydrogel under an infinite
dose regimen. (C) Biodistribution of ketorolac 24 h after application of KT hydrogel using a finite dose
regimen. Around 95% ketorolac remains outside the skin while the successfully penetrated ketorolac
is retained within the stratum corneum and epidermis layers. All values represent Means ± SD
(n = 6). Different Greek letters represent significant differences (p < 0.001).
Gels 2021, 7, 8 8 of 20
Permeation of ketorolac across different tissues (skin or vaginal mucosa) upon applica-
tion of KT hydrogel showed significant differences. In case of permeation across skin tissue,
the permeation parameters indicate that ketorolac permeation reached the steady state
from the very beginning, with an estimated Tlag of 0.67 h, and showing a transdermal flux
of 50.92 µg/h·cm2, leading to a total amount of ketorolac permeated of 1202.46 µg/cm2
after 24 h. In contrast, permeation through vaginal mucosa indicated a slightly longer
Tlag (2.04 h) while a significantly higher flux (306.00 µg/h·cm2) led to a similar amount of
ketorolac permeated (1102.20 µg/cm2) in only 6 h.
Table 2. Transdermal/transmucosal permeation parameters of ketorolac 24 h/6 h after application
of KT hydrogel under an infinite dose regimen. Results are expressed as Mean ± SD (n = 6). AP:
amount of ketorolac permeated after 24 h/6 h. AR amount retained after 24 h/6 h. Css: plasma
concentration at steady state. Tlag: lag time. Jss: transdermal/transmucosal flux.
Skin Vaginal Mucosa
AP (µg/cm2) 1202.46 ± 143.99 1102.20 ± 212.08
AR (µg/cm2) 52.54 ± 14.71 1090.42 ± 196.27
Css (µg/mL) 0.22 ± 0.01 1.30 ± 0.05
Tlag (h) 0.67 ± 0.003 2.04 ± 0.50
Jss (µg/h·cm2) 50.92 ± 1.44 306.00 ± 6.95
Kp (cm/h) 2.55 × 10–3 1.53 × 10–2
These results can be explained by the fast release of ketorolac from KT hydrogel
(Figure 4) as well as by the physicochemical properties of the drug (QSAR). For instance,
it is considered that drugs with a molecular weight below 500 Da, an octanol: water
partitioning coefficient (log P) below 5, less than 5 hydrogen bound donors, and less than
10 hydrogen bound acceptors, can successfully permeate through skin tissue [23,24]. These
properties change when the drug is in its neutral form (ketorolac) or in the salt form
(ketorolac tromethamine). For instance, the salt form has a higher molecular weight than
the neutral form (376.4 vs. 255.27 g/mol), more hydrogen bond donors (5 vs. 1), more
hydrogen bond acceptors (7 vs. 3), and although the log P for the salt form is not reported,
it is expected to be much lower than that of the neutral form (1.9) [25,26]. It is true that the
drug in contact with biological medium may change its form (and thus its properties), being
in an equilibrium that depends on the concentration of the drug and the composition of
the medium in which it is dissolved. Changes can include exchange of the cationic moiety
(tromethamine) for other cations or protonation of the carboxylate group of ketorolac to a
neutral carboxylic acid. Nonetheless, the use of the salt form in KT hydrogel may initially
influence a higher proportion of ketorolac molecules in the salt form. For this reason,
the faster permeation of ketorolac through the vaginal mucosa may be especially related to
the highly hydrophilic behavior of the salt form (ketorolac tromethamine), as it does not find
an important lipophilic barrier against the penetrating of the tissue and permits high fluxes
across the mucosa. In contrast, permeation of ketorolac through the skin is compromised
by the barrier effect produced by the epidermis (especially the highly lipophilic stratum
corneum), leading to smaller fluxes. Examples of gels for topical application can be found
in the literature showing that the physicochemical properties of the drug highly influence
their ability to permeate through the skin. When applied using the same gel and at the same
concentration, neutral, lipophilic drugs such as the corticoids betamethasone 17-valerate or
triamcinolone acetonide tend to permeate faster than cationic drugs such as gemcitabine
hydrochloride or anionic drugs such as methotrexate sodium [20].
Moreover, local anti-inflammatory activity with a rapid action onset may be achieved
by a sufficient amount of drug retained in the tissue in short time. In this regard, short
Tlag was observed in both tissues, and the total amount of ketorolac retained within the
skin was 52.54 µg/cm2, whereas within vaginal mucosa was around 20 times higher
(1090.42 µg/cm2). These results confirm the suitability of KT hydrogel for local application
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in either tissue but especially on vaginal mucosa, as the higher retention is most probably
related to the higher contents of water in the tissue.
In order to assess a possible systemic effect after application of KT hydrogel under
an infinite-dose regimen, either on skin or vaginal mucosa, the steady state plasma con-
centration (Css) after application of ketorolac gel was estimated, considering the human
plasma clearance of ketorolac (1840 mL/h) [27] for a mean 80-kg individual. For instance,
the expected Css achieved after application of these hydrogel considering a hypothetical
area of application of 5 cm2 would be 0.22 µg/mL when applied on human skin, whereas
1.30 µg/mL when applied on vaginal mucosa. The therapeutic plasma concentration range
reported is 0.3 to 5 µg/mL [28]; thus, the Css expected after a dermal application would
be below the therapeutic plasma concentration range. On the contrary, the Css calculated
after a 5 cm2 vaginal application would be within this reported range. However, no side
effects would be expected since the Css is close to the lower limit. Additionally, topical
products are not used in exaggerated use conditions (infinite dose approach) but in finite
dose conditions. All this suggests that the KT hydrogel could be safely used for the local
healing of inflammation. The equations for the calculation of Css and of the absorption
parameters can be seen in the Appendix A (permeation parameters and calculation of the
Css upon application of KT hydrogel).
2.4. Distribution of Ketorolac within the Skin Layers
A permeation experiment under finite dose regimen [22] was performed to study the
skin biodistribution of ketorolac. For instance, around 10 µL of gel was applied on the
skin, the dose of ketorolac trometamine being only 102 µg/cm2. After 24-h permeation,
the receptor fluid was collected. Ketorolac remaining on the surface of the skin was
carefully recovered, adhesive tape was used to perform stripping procedures to detach
the stratum corneum, and the epidermis was then separated from the dermis by means
of heat. Ketorolac contained in the adhesive tapes, the epidermis, and the dermis was
extracted using a water:methanol mixture from the different layers and finally was analyzed
(Figure 5C). Detailed absolute and relative amounts can be seen Table 3. After application
of a small amount of KT hydrogel, most of the ketorolac could be recovered (92–101%).
Approximately 95% of the dose applied was not absorbed, rather it was found on the
surface, which can be related to the barrier effect produced by the highly lipophilic stratum
corneum [29].
Table 3. Distribution of ketorolac within the skin layers 24 h after application of KT hydrogel under
a finite-dose regimen. b.l.q. stands for ‘below limit of quantification’
KT Hydrogel Application µg/cm2 %
Ketorolac trometamine dosed 102.09 100.00
Surface 96.72 ± 4.07 94.75 ± 3.99
Stratum corneum 1.02 ± 0.84 1.00 ± 0.82
Percutaneous absorption 0.40 ± 0.32
Epidermis 0.40 ± 0.32 0.39 ± 0.32
Dermis 0.002 ± 0.001 0.002 ± 0.001
Receptor fluid b.l.q. b.l.q.
Total recovery 98.14 ± 4.69 96.14 ± 4.60
Regarding the drug penetrated into the skin, around 1% was found in the stratum
corneum, 0.4% was found in the epidermis, and only 0.002% in the dermis, whereas no
ketorolac was detected in the receptor fluid. This indicates no drug is absorbed into the
systemic circulation when applying a small dose. This biodistribution suggests that upon
application of small doses, finding the drug in the outer layers of the skin is not related to
the affinity of the drug for these (lipophilic) layers, but is due to the low dose applied. In
the beginning, the high drug concentration gradient at the surface of the skin promotes the
Gels 2021, 7, 8 10 of 20
diffusion inside the skin, but the low dose leads to a rapid decrease in the concentration
gradient, impeding the further diffusion along the inner epidermis layers.
Therefore, the application of a small dose such as 10 µL on the skin would probably
lead to anti-inflammatory activity in the outer layers of the skin only; however, when the
KT hydrogel is applied in higher quantities, such as those used under the infinite dose
regimen (~200 µL), it should be effective for the topical relieve of inflammatory processes,
either applied through the skin or through vaginal mucosa.
2.5. In Vivo Anti-Inflammatory Efficacy Evaluation
To assess if the ketorolac retained within the skin after application (Sections 2.3 and 2.4
ex vivo permeation experiments under finite and infinite-dose approaches) is sufficient to
develop a local anti-inflammatory effect, an in vivo study was carried out in mice. Groups
of mice (n = 6) were processed in parallel. In all groups, acute skin edema was induced
upon application of TPA in both ears of the mice. At the same time, in one of the groups,
KT hydrogel was applied to the right ear of the mice as a treatment, whereas 2% solution
of ketorolac tromethamine in water was applied to the right ear in a second group, and
finally, hydrogel without drug was applied to the right ear in a third group.
The inhibition of inflammation achieved by the KT hydrogel as well as by the ketorolac
tromethamine solution or the hydrogel without drug was calculated and is shown in
Figure 6C.
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Figure 6. (A) Hydration of the stratum corneum upon application of KT hydrogel in humans. (B) Trans-epidermal water loss
(TEWL) expressed in g of water per hour per 2 of skin, upon application of KT hydrogel in humans. (C) Anti-inflammatory
activity expressed as inhibition (%) of TPA-induc d inflammation upon appl cati n of a treatment (KT hydrogel, ketorolac
tromethamine in solution, and hydrogel without drug). Values represent Means ± SD (n = 6). * Significant differences
(p < 0.05); *** Significant differences (p < 0.001) as compared to control (hydrogel without drug).
The application of KT hydrogel led to a 52.9% reduction of inflammation as compared
to the positive control, while application of ketorolac tromethamine in solution led to a
24.5% reduction of inflammation. However, KT hydrogel showed itself to be 2.16 times
more effective than ketorolac tromethamine in solution, suggesting that the clinical appli-
cation of KT hydrogel could be suitable for producing local anti-inflammatory activity.
2.6. In Vivo Tolerance Study
The preservation of the integrity of the skin upon application of KT hydrogel was
studied using a corneometer. Parameters such as the hydration of the stratum corneum or
the trans-epidermal water loss (TEWL) were analyzed and are shown in Figure 6A,B. Re-
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sults show that upon application of the hydrogel, the basal hydration levels of the stratum
corneum (55.9 ± 1.9 AU) decreased by 28%, reaching values of 40.3 ± 1.3 AU, 45 min after
application, but gradually recovered to the initial values after 4 h. According to the normal
values of skin hydration [30], values comprehended between 30 and 45 AU could be related
to moderately dry conditions, while values above 45 AU could be related to a sufficiently
hydrated skin. Thus, the application of KT hydrogel may result in only moderate dehy-
dration, a condition that is reversible in the short term. The moderate dehydration of the
stratum corneum could be explained by the highly hydrophilic behavior of the sodium
alginate fibers forming the gel, that in contact with the stratum corneum may absorb the
water from the surroundings, a behavior that was also observed in swelling experiments.
Likewise, TEWL is an indirect measure of skin permeability and the barrier function
of the stratum corneum by observing the speed at which water is being evaporated from
the surface [31]. It is generally accepted that TEWL values from patients with intact skin
can range between 6 and 13 g h–1 m–2. In this study, untreated patients showed TEWL
values of 11.1 + 0.7 g h–1 m–2, while upon application of KT hydrogel, TEWL values
increased to 13.9 + 0.1 after 45 min and reached a maximum of 15.4 + 0.4 after 2.7 h but
later decreased to basal values after 3.7 h. These results show that the application of KT
hydrogel may slightly disrupt the barrier function of the stratum corneum but only to
an extent which does not represent any threat to the physiological function of the skin,
since TEWL values revert to the basal one in a few hours. The diffusion across a lipophilic
structure, such as the stratum corneum, may be challenging for a highly water-soluble drug
such as ketorolac tromethamine, and the hydrogel might be exerting a boost action on the
Ketorolac’s penetration by modifying the vehicle-skin partition coefficient in a reversible
manner by promoting the water content in the stratum corneum, and the water embedded
in the hydrogel might drive the Ketorolac diffusion through the stratum corneum.
Studies have shown that skin variables such as TEWL, pH, and skin temperature in
humans are dependent on circadian rhythms, interestingly finding that the skin perme-
ability is higher during the evening and late night than in the morning [32]. Moreover, it
has been shown in hairless rats that changes in the environmental temperature and light
have an effect on skin function [33]. This suggests that the reversible TEWL values of the
skin after application of KT hydrogel might be influenced by circadian rhythms and/or
environmental factors such as temperature, and this suggests that its application during
the evening might lead to higher analgesic and anti-inflammatory efficacy.
In addition, the application of KT hydrogel on patients’ skin did not lead to any visual
irritation and was well tolerated.
3. Conclusions
An alginate-based hydrogel was extensively characterized in terms of morphology,
pH, physical stability, and mechanical properties, showing adequate characteristics for a
topical formulation.
Drug release studies show that up to 73% of the total amount of ketorolac in the gel can
be released in less than 6 h from the hydrogel following the one-phase exponential model.
Permeation experiments under an infinite-dose approach were performed using hu-
man skin and vaginal mucosa, demonstrating that ketorolac contained in the hydrogel
can permeate through both tissues successfully, showing almost 7 times faster permeation
through vaginal mucosa (306.0 µg/h·cm2) than through human skin (50.92 µg/h·cm2).
Moreover, ketorolac is retained within the tissue 24 h/6 h after application, showing an up
to 20-times higher amount of drug retained within vaginal mucosa (1090.42 µg/cm2) than
in human skin (52.54 µg/cm2).
The topical application of this hydrogel, in general, should not cause any systemic
side effects, and therefore, it can be considered safe.
The hydrogel was well tolerated in vivo when applied in humans, showing no im-
portant alterations in the skin barrier function such as hydration and TEWL. Additionally,
the hydrogel did not cause any visible irritation. These results show that KT hydrogel is a
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stable and suitable formulation for the treatment of inflammatory processes, such as those
occurring upon chemical or surgical removal of anogenital warts.
4. Materials and Methods
4.1. Materials
4.1.1. Reagents
Sodium alginate was purchased from Fagron Iberica (Terrassa, Spain). Ketorolac
tromethamine and Nipagin were obtained from Sigma-Aldrich (Barcelona, Spain). Nipasol
was acquired from Acofarma (Barcelona, Spain), and Na2HPO4 and KH2PO4 were supplied
by Panreac (Barcelona, Spain). PBS pH 7.6, gentamicin sulphate, and bovine serum albumin
were provided by Sigma (St. Louis, MO, USA); methanol was obtained from Merck,
Darmstadt, Germany. The adhesive tapes were obtained from D-squame, (Cuderm Co.,
Dallas, TX, USA).
The purified water was obtained from a Milli-Q1 Gradinet A10 system apparatus
(Millipore Iberica S.A.U., Madrid, Spain). All the other chemicals and reagents used in the
study were of analytical grade.
4.1.2. Tissues and Experimental Animals for Ex Vivo and In Vivo Assays
Human skin was obtained from abdominoplasties on healthy women (Barcelona
SCIAS Hospital, Barcelona, Spain). The Bioethics Committee of the Barcelona-SCIAS
Hospital approved the Study protocol (Nº001; approved on 20/01/2016), and volunteers
provided written informed consent forms.
Following the surgery, the skin was stored at −20 ◦C until the experiments; then,
the skin was dermatomed (GA630, Aesculap, Tuttlingen, Germany) at 500 µm-thick. The
human skin barrier integrity of all skin discs was determined by transepidermal water
loss (TEWL) using a TEWL-meter (Dermalab) prior to the permeation studies. Those skin
discs that failed in the skin barrier integrity stage (TEWL values above 13 g/m2 h) were
discarded and replaced.
Vaginal mucosa (Landrace Large White race) was provided by the Bellvitge animal
facility services. The Ethics Committee of Animal Experimentation of the University of
Barcelona approved the Study Protocol (approved on 10/01/2019). Full-thickness mucosa
was used in the permeation studies.
Male Swiss CD-1 mice weighing 20–25 g (Círculo ADN S.A. de C.V.; Coyoacan D.F.,
Mexico) were used for the in vivo anti-inflammatory efficacy evaluation after a 7-day
quarantine period. The animals were housed in plastic cages with soft bedding, controlled
diet, and tap water ad libitum. Environmental conditions were controlled at 24 ± 1 ◦C,
and the relative humidity was kept at 50–60%. Light conditions were also controlled, being
12 h light and 12 h dark every 24 h.
The study was performed according to the Mexican Official Normative for Animal
Care and Handling (NOM-062-ZOO-1999), and the Academic Ethics Committee of the
Vivarium at the Universidad Autónoma del Estado de Morelos (Mexico) approved the
Study Protocol (BIO-UAEM:012:2013; approved on 21/12/2015).
4.2. Preparation of Sodium Alginate Hydrogels
Drug-loaded hydrogels were prepared at laboratory scale at a concentration of 2%
w/v by dissolving ketorolac tromethamine in aqua conservans. Sodium Alginate (4%) was
gradually added to the ketorolac tromethamine solution with continuous stirring, until a
thin dispersion without residual powder was formed. The dispersions were allowed to
equilibrate in a water bath at 37 ◦C for 24 h so that they would undergo the swelling process
that led to the formation of a cross-linked polymeric network, obtaining KT hydrogel.
The gel was stored at room temperature.
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4.3. Physical Characterization of KT Hydrogel
4.3.1. Appearance
The hydrogel formulation was visually observed directly for color, odor, and viscosity,
at preparation and again 2 months afterwards.
4.3.2. pH Measurements
The pH of the hydrogel was measured at room temperature using the pH meter
micro-pH 200 (Crison Instruments S.A., Barcelona, Spain). Measurements were conducted
with the gel freshly prepared and at 2 months after preparation.
4.3.3. Optical Stability
The physical stability of the KT hydrogel was monitored by Dynamic Backscattering
using a TurbiScanLab® (Turbiscan T-Lab Expert (Formulaction Co., L’Union, France).
The optical sensor comprises a pulsed near-infrared light source and two synchronous
optical sensors: one for backscattering and one for transmission.
A volume of 20 mL of KT hydrogel was filled into flat-bottom cylindrical glass measur-
ing cells, and backscattered light at λ = 880 nm was measured from the top to the bottom
of the vial, hourly for 24 h at 25 ◦C to evaluate the short-term stability. Measurements were
repeated two months later to assess the long-term stability. Hydrogel without drug was
analyzed similarly as a control [34].
4.3.4. Morphological Studies
The micro-structure of the hydrogel was examined by Scanning Electron Microscopy
(SEM) in a JSM-7100F (JEOL Inc., Peabody, MA, USA) by coating the sample with a thin
layer of carbon in an Emitech K950 coater (Quorum Technologies Ltd., Kent, UK).
4.3.5. Swelling and Degradation Tests
The swelling test evaluates the hydrogel capacity of absorbing water within its struc-
ture. The PBS uptake was carried out in triplicate by determining the swelling ratio (SR) by





where Wd is the weight of dried hydrogel, and Ws is the weight of the swollen hydrogel at
different times.
Briefly, the dried hydrogel was immersed in PBS (pH = 7.4) at 37 ◦C for 90 min.
At different times (2, 5, 10, 20, 30, 60, and 90 min), the gel was removed from the incubation,
and the excess PBS on the gel surface was soaked up and then weighed (Ws).
The degradation test aims to monitor the weight loss as a function of time. The weight
loss (WL) was calculated by incubating known amounts of fresh hydrogel in PBS (pH = 7.4)
at 37 ◦C for 21 h. Three replicates of hydrogel were removed, blotted, and weighed at
the following time points: 0.08, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 8, and 21 h. The weight loss was
expressed as the percentage of weight loss with respect to the freshly prepared hydrogel. It





where Wi is the initial weigh of hydrogel and Wd the weight of hydrogel at different times.
4.3.6. Rheological Behavior
The rheological properties of the sodium hydrogel containing 2% ketorolac
tromethamine were determined by a rotational Haake RheoStress 1 rheometer (Thermo
Fisher Scientific, Karlsruhe, Germany) equipped with cone-plate geometry (Haake C60/2◦
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Ti, 60 mm diameter, 0.105 mm gap between cone-plate). Measurements were performed in
duplicate at 32 ◦C (Thermo Haake Phoenix II + Haake C25P), the program consisted of a
3 steps shear profile: (1) a ramp-up period from 0 to 100 s−1 during 3 min, (2) followed by
a constant shear rate period at 100 s−1 for 1 min, and (3) the ramp-down period from 100
to 0 s−1 for 3 min. Steady-state viscosity, determined at t0, at 32 ◦C, was also calculated
from the constant shear stretch at 100 s−1.
The flow data obtained were fitted to different mathematical models (Table 4) to
describe the flow curve and characterize the flow properties:




Newton τ = η· .γ
Bingham τ = τ0 + (η0·
.
γ)
Ostwald–de Waele τ = K· .γn





















where, τ is the shear stress (Pa), η is the dynamic viscosity (mPa·s), .γ is the shear rate (1/s), τ0 is the yield shear
stress (Pa), η0 is the zero-shear rate viscosity, ηp is a constant plastic viscosity (mPa·s), η∞ is the infinity shear rate
viscosity, n is the flow index, and K is the consistency index. The goodness of fit was determined by correlation
coefficient (r) by linear regression analysis of the flow plots.
4.4. In Vitro Release of Ketorolac from the Hydrogel
The in vitro release assay was conducted using amber glass Franz diffusion cells (Franz
Diffusion cells (FDC 400, Crown Glass, Somerville, NY, USA) with an active diffusion
area of 1.77 cm2 (n = 6). The receptor fluid consisted of 0.06M PBS (pH 7.4), which
was continuously stirred with magnetic beads at 500 rpm to keep the contents of the
receptor compartment homogeneous throughout the tests. The system was thermostatted
at 37 ± 0.5 ◦C by a circulating water jacket. Sink conditions were held throughout the
experiments, and 310 mg ± 10 mg of KT hydrogel was accurately applied to the membranes
(mixed ester cellulose 0.45 µm pore size) in the donor compartment. Air bubbles entrapped
below the membranes were removed, and the system was allowed to equilibrate for at
least 30 min before applying the hydrogel. Parafilm was used to avoid evaporation by
sealing the donor compartment and the sampling ports. Samples (300 µL) were collected
at specific time intervals for about 20 h (1, 2, 4, 5.5, and 19.75 h), and the same volume
was immediately replaced with PBS after the removal of each sample. The ketorolac was
determined by High Performance Liquid Chromatography (HPLC) following the norms
of a validated method, and the experimental data were fitted to different mathematical
models (Zero-order, First-order, and Higuchi) (See Appendix A, Mathematical models
fitted to drug release experiments). The best fitting model was chosen according to the
correlation coefficient (r2) value.
4.5. Ex Vivo Permeation of Ketorolac through Human Skin and Vaginal Mucosa
The penetration and permeation of Ketorolac into and through the skin was evaluated
by infinite dose and by finite dose approaches. The former provided information about
the kinetics and permeation parameters (Sections 4.5.1–4.5.3), and the finite dose setup
provided information about the distribution of Ketorolac within the skin, in its different
layers with a realistic application approach (Section 4.6).
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4.5.1. Infinite Dose Approach Ex Vivo Permeation Assay in Human Skin
To study the rate and extend of Ketorolac that diffused through the skin, an ex vivo
permeation assay was performed. The experiment was conducted as designed for the
release assay except that 500-µm dermatomed frozen skin was used instead of synthetic
membrane (n = 6). The skin was thawed at room temperature, and skin discs were punched
and mounted on the Franz cell (0.64 cm2 of diffusion area) with the Stratum Corneum
facing up to the donor compartment and the dermis in contact with the receptor fluid [35].
Hydrogel (200 mg) was applied to the skin, and samples (300 µL) were collected at the time
intervals: 0, 3, 6, 8, 10, 19.75, 20.75, and 24 h and stored at −20 ◦C until sample analysis by
HPLC was carried out.
4.5.2. Infinite Dose Approach Ex Vivo Permeation Assay in Porcine Vaginal Mucosa
The ex vivo permeation test with full-thickness porcine vaginal mucosa aimed at in-
vestigating the capacity of ketorolac to diffuse through the vaginal tissue. It was conducted
in the same manner as in Section 4.5.1, adjusting the sampling times to: 1, 2, 3, 4, 5, and
5.7 h. Samples were stored and analyzed by HPLC.
Results from the permeations assays fitted to a zero-order kinetic model, by means of
a linear least squares regression, and the permeation parameters were calculated according
to the equations described in Appendix A (Permeation parameters and calculation of the
Css upon application of KT hydrogel).
4.5.3. Amount of Ketorolac Retained in the Skin and in the Vaginal Mucosa
At the end of the permeation assays, the residual hydrogel on the skin or mucosa
was removed by a swab, and the tissues were taken out of the Franz cells, cleaned with a
gauze soaked in 0.05% solution of sodium lauryl sulfate and rinsed 3 times with distilled
water. The permeation area of the skin/vaginal mucosa was then cut and weighed and
perforated by a thin needle and incubated with 1 mL of methanol: water (1:1) to extract
the Ketorolac remaining in the tissues. The mixtures were sonicated for 20 min., and the
supernatants were pipetted and analyzed by the HPLC method, yielding the amount of
ketorolac retained in the tissues.
4.6. Distibution of Ketorolac within the Skin Layers
The distribution of Ketorolac within the skin layers was assessed by ex vivo perme-
ation assays in finite dose approach using human skin dermatomed at 500 µm. Skin discs
were placed on thermostated (32 ◦C) Franz static diffusion cells (3 mL, 1.86 cm2 of exposed
area, Lara-Spiral, Courtenon, France). The sink conditions were guaranteed throughout
the assay by adding bovine serum albumin 1% (w/v) in the receptor fluid, which was PBS
at pH 7.6, gentamicin sulphate 0.04% (w/v) was also added to prevent skin degradation [9].
The receptor fluid was under magnetic stirring throughout the assay. A volume of 10 µL of
hydrogel was applied to the skin. Control cells were also used with placebo hydrogel to
evaluate any potential interferences in the sample analysis of the receptor fluid samples or
skin samples. After 24 h of exposition, the skin discs were demounted from the Franz cells
and the residual hydrogel (either with or without Ketorolac) remaining on the skin surface
was recovered. The receptor fluid was recovered, and the stratum corneum was isolated by
the tape-stripping technique. Twelve strips were carried out to remove most of the Stratum
corneum. The epidermis was separated from the dermis by heat treatment [9]. The skin
samples were incubated in water:methanol (1:1, v/v) and sonicated for 20 min to extract
the Ketorolac. The extraction solvent volume was 10 mL for the skin surface, 2 mL for the
Stratum corneum and Epidermis, and 1 mL for the Dermis. The supernatants were pipetted
and analyzed by the HPLC method. The amounts of ketorolac in each compartment are
expressed as µg/cm2 and % of the applied dose.
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4.7. Analysis of Ketorolac in Solution
The samples generated in the in vitro release and in vitro permeation studies were
analyzed by a validated HPLC method. The chromatographic conditions were the follow-
ing: the mobile phase consisted of acetonitrile (+0.065% triethylamine) and purified water
(+0.165% acetic glacial acid), in an isocratic elution (1:1) at flux 1 mL/min. The column
used was Symmetry C18 75 mm × 4.6 mm and 3.5 µm. The volume injected was 10 µL,
and Ketorolac was determined at the wavelength of 314 nm.
4.8. In Vivo Anti-Inflammatory Efficacy Evaluation
The anti-inflammatory efficacy of the hydrogel was evaluated in accordance with
the methodology described by Mallandrich et al. [9], which consisted of inducing an ear
oedema inflammation on mice by 12-O-detradecanoylphorbol-13-acetate TPA. Swelling
is caused by fluid accumulation in the interstitial tissue after vasodilation; this greater
fluid retention, in turn, increases the weight of the ear, and it is correlated with the
inflammatory/anti-inflammatory response.
Briefly, a TPA solution was prepared in ethanol at 0.05%. The animals were divided
in 3 groups (n = 6), which were processed in parallel: group 1, KT hydrogel; group 2,
2% solution ketorolac tromethamine in water; and finally, group 3, hydrogel without
drug. In all groups, acute skin edema was induced upon application of 5 µL TPA in the
mice’s left ears, which served as 100% inflammation control. An equivalent volume of
TPA was applied to the right ear of the animals and subsequently, 100 mg of formulation
(KT hydrogel, ketorolac solution or placebo hydrogel, depending on the group) was also
applied to the mice’s right ear as treatment.
At 4 h post-application, the animals were slaughtered, and 7-mm circular sections were
cut from both ears and weighed to determine the anti-inflammatory activity. The inhibition
of inflammation achieved by the KT hydrogel as well as by the ketorolac tromethamine
solution or the hydrogel without drug was calculated according to the Equation (3):
Inhibition (%) =
(




4.9. In Vivo Tolerance Study
Variations in the skins biomechanical properties were evaluated after the hydrogel ap-
plication compared to the basal conditions. The parameters assessed were the Transepider-
mal water loss (TEWL–Dermalab), and the Stratum corneum hydration (SCH–Corneometer
Courrage CM825). To this end, healthy subjects participated as volunteers in this study
with prior approval of the Study Protocol by the Ethics Committee University of Barcelona
(IRB00003099; approved on 20/03/2018). Six women—aged between 21 and 64—who gave
their informed consent were asked to abstain from the application of cosmetics 6 h prior to
the test. They had a 20 min adaption period to acclimate themselves to the room conditions
before each measurement. Prior to the hydrogel application, the site of application was
marked by a template, and the basal values of TEWL and SCH were recorded for the test
areas. Then, the hydrogel was applied homogenously as a thin layer to each volunteer’s
left forearm. The following readings were performed at different time points for about 4 h
(15, 45, 105, 165, 225, and 255 min).
4.10. Statistical Analysis
The cumulative amounts of the drug released and permeated over time were deter-
mined using linear regression analysis. The influence of the KT hydrogel on the TEWL and
hydration of the skin was analyzed by one-way analysis of variance (ANOVA) at the time
points. The significance level was set to 0.05.
GraphPad Prism®, v. 5.00 software (San Diego, CA, USA) was used for all statistical
calculations.
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ANOVA One-way analysis of variance
AP Amount ok ketorolac permeated












HPLC High Performance Liquid Chromatography
HPV Human Papilloma Virus
J Flux
Jss Flux at steady state
K Release rate constant
Kg Kilogram
KH2PO4 Potassium dihydrogen phosphate
Kp Permeability coefficient
KT Ketorolac tromethamine
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Appendix A
Appendix A.1. Mathematical Models Fitted to Drug Release Experiments
The amount of ketorolac released from the gels was fitted to the following model
equations [36]:
Table A1. Equations of the kinetic models fitted.
Zero-order Rt = R∞ + Ko × t




Higuchi Rt = R∞ + Kh × t1/2
where Rt is the amount of drug released at time t, R∞ is the maximum amount of drug released, K is the release
rate constant expressed in units of concentration/time, and n is the diffusion release exponent that can be used to
characterize the different release mechanisms. It has been established that n ≤ 0.43 (Fickian diffusion mechanism),
0.43 < n < 0.85 (anomalous transport) and n ≥ 0.85 (Super case II transport, i.e., zero, order release) [36].
The best fitting model was chosen according to the correlation coefficient (r2) value
(Table A1), for which drug release was determined to follow a First-order (one-phase
exponential association) kinetics.





Appendix A.2. Permeation Parameters and Calculation of the Css upon Application of
KT Hydrogel
The steady state plasma concentration (Css) was calculated assuming an area of




where Css is the steady state plasma concentration (Css), J (µg/h) is the flux, TSA (cm2) is
the theoretical surface area of application, Clp (mL/min) is the human plasma clearance
of ketorolac, and A (cm2) is the diffusion area of the Franz cells. An area of application of
5 cm2 was assumed.





where Kp is the permeability coefficient of ketorolac through the membranes; J (µg/h) is
the flux, and C0 (µg/mL) is the initial concentration of ketorolac in the gel.
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